Dong Q H, Handelsman D J
Department of Obstetrics and Gynecology, University of Sydney, New South Wales, Australia.
Endocrinology. 1990 Mar;126(3):1498-503. doi: 10.1210/endo-126-3-1498.
Previous studies have demonstrated that abolition of the naloxone-stimulated increase in plasma LH levels is characteristic of hypothalamic dysfunction in experimental uremia. This study aimed to further characterize the nature of the defect in hypothalamic opiatergic mechanisms in experimental uremia. Specifically, we have tested the hypothesis that naloxone resistance was due to either opioid receptor dysfunction or diminished opioid peptide levels. Administration of naloxone (2 mg/kg, iv) to cannulated freely mobile rats confirmed previous observations that despite marked increases in plasma LH in control rats, plasma LH levels were unaffected in uremic male rats (P = 0.001 for group x time interaction). In a second experiment, morphine (2 mg/kg) or saline diluent was given quasi-continuously as small aliquots before each blood sample during the pulse studies of castrate mature male rats that had undergone either subtotal nephrectomy or sham operation. After the administration of morphine, uremic rats exhibited a 60% reduction in mean LH levels (14.9 +/- 1.4 vs. 6.0 +/- 0.7 ng/ml) attributable to a 42% reduction in LH pulse frequency (3.6 +/- 0.4 vs. 2.1 +/- 0.5 peaks/3 h) and a 60% reduction in LH pulse amplitude (4.7 +/- 0.5 vs. 1.9 +/- 0.3 ng/ml). The preservation of sensitivity to morphine despite complete naloxone resistance raised the alternate hypothesis of depletion of endogenous opiate peptide levels in the uremic hypothalamus. This hypothesis was tested by measuring the beta-endorphin content of the medial basal hypothalamus (MBH) in a rat beta-endorphin RIA. Rat MBH beta-endorphin content was not significantly altered specifically by either uremia or castration. We conclude, therefore, that naloxone resistance of plasma LH in experimental uremia is not due to either defects in opioid receptor function or reduced hypothalamic beta-endorphin content. Instead, we suggest that uremia may diminish the release of endogenous opioid peptides that interact with GnRH neurons from the MBH.
先前的研究表明,实验性尿毒症下丘脑功能障碍的特征是纳洛酮刺激后血浆促黄体生成素(LH)水平升高被消除。本研究旨在进一步明确实验性尿毒症下丘脑阿片能机制缺陷的本质。具体而言,我们检验了以下假设:纳洛酮抵抗是由于阿片受体功能障碍或阿片肽水平降低所致。对插管的自由活动大鼠静脉注射纳洛酮(2mg/kg),证实了先前的观察结果,即尽管对照大鼠血浆LH显著升高,但尿毒症雄性大鼠的血浆LH水平未受影响(组×时间交互作用,P = 0.001)。在第二项实验中,对行次全肾切除术或假手术的去势成熟雄性大鼠进行脉冲研究时,在每次采集血样前,以小份剂量准连续给予吗啡(2mg/kg)或生理盐水稀释剂。给予吗啡后,尿毒症大鼠的平均LH水平降低了60%(14.9±1.4 vs. 6.0±0.7ng/ml),这归因于LH脉冲频率降低了42%(3.6±0.4 vs. 2.1±0.5个峰值/3小时)以及LH脉冲幅度降低了60%(4.7±0.5 vs. 1.9±0.3ng/ml)。尽管对纳洛酮完全抵抗,但对吗啡的敏感性得以保留,这引发了另一种假设,即尿毒症下丘脑内源性阿片肽水平耗竭。通过大鼠β-内啡肽放射免疫分析(RIA)测量内侧基底下丘脑(MBH)的β-内啡肽含量,对这一假设进行了检验。尿毒症或去势并未特异性地显著改变大鼠MBH的β-内啡肽含量。因此,我们得出结论,实验性尿毒症中血浆LH对纳洛酮的抵抗并非由于阿片受体功能缺陷或下丘脑β-内啡肽含量降低。相反,我们认为尿毒症可能会减少与来自MBH的促性腺激素释放激素(GnRH)神经元相互作用的内源性阿片肽的释放。